On September 1, 2022 Singapore-based biotech start-up, Axcynsis Therapeutics, reported that achieves its important milestone three months after its fund-raising announcement (Press release, Axcynsis Therapeutics, SEP 1, 2022, View Source [SID1234618862]). Located at Singapore’s biotech hub, The Science Park 2, Axcynsis opens its first office and research facility spanning approximately 4000 square feet.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Our Biology, Chemistry and Bioconjugation laboratories, furnished with state-of-the-art equipment for Antibody-X conjugate discovery, will lay the foundation for Axcynsis’ innovation to further strengthen our discovery platforms." said Dr. Zou Bin, founder and CEO of Axcynsis Therapeutics.

Following this opening, Axcynsis Therapeutics looks to further expand the growing team to work towards its mission in developing the next generation Antibody-X conjugates.